FSC LaboratoriesTo Market Aciphex® Sprinkle™ (Rabeprazole Sodium) In The U.S.
6/30/2014 10:37:42 AM
CHARLOTTE, N.C.--(BUSINESS WIRE)--FSC Therapeutics, LLC, today announced that the Company has entered into a transaction with Eisai Inc. to acquire exclusive U.S. marketing rights for AcipHex® Sprinkle™ (rabeprazole sodium), Delayed-Release Capsules, 5 mg and 10 mg, for the treatment of Gastroesophageal Reflux Disease (GERD) in children 1 to 11 years of age for up to 12 weeks. AcipHex Sprinkle will be distributed by FSC Laboratories, Inc., and promoted by its subsidiary, FSC Pediatrics, Inc., to pediatric primary care-focused practitioners across the U.S.
Help employers find you! Check out all the jobs and post your resume.
comments powered by